Spring Sciences Australia is nearing a decision on whether to pursue an ASX listing or raise […]
Spring Sciences Australia weighs ASX float against private raise after difficult 2025
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
ASX IPO
ATO
Australian Taxation Office
mergers and acquisitions
Office of Drug Control
private capital raise
Spring Sciences Australia
Steve Newbery
Related Articles
